-
NaviFUS begins clinical trial for brain tumour treatment
europeanpharmaceuticalreview
August 06, 2021
NaviFUS® was approved by the Taiwan, China FDA for use in a new clinical trial for the treatment of terminal primary brain tumours.
-
NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors
prnasia
August 04, 2021
NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS®) was recently approved for use in a new clinical trial by the Taiwan, China Food and Drug Administration (TFDA).
-
OncoSynergy Announces First Patient Treated in OS2966 Trial of Recurrent Glioblastoma
americanpharmaceuticalreview
March 10, 2021
OncoSynergy announced the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.
-
PeptiDream and Shionogi sign peptide drug conjugate discovery deal
pharmaceutical-technology
January 24, 2019
PeptiDream has signed a deal with fellow Japanese pharmaceutical company Shionogi to discover and develop a series of blood-brain barrier (BBB) penetrating peptide drug conjugates.
-
Scorpion venom could hold the key to breaching the blood-brain barrier
pharmaceutical-technology
November 26, 2018
The Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a small protein (a peptide) derived from chlorotoxin...
-
Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena
pharmafocusasia
November 05, 2018
Bioasis Technologies Inc., a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery...